Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 Sarepta Therapeutics, today provided the following update on the Biologics …
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001Read More
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne …
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular …
The story behind Ruth’s charity dinner dance
The story behind Ruth's charity dinner dance Ruth and Ian Taylor tell us about their journey with Duchenne so far in this inspiring interview. Ruth …
Take part in our Turning Point survey for a chance to win a £20 Amazon Voucher!
We need you! Are you a parent/caregiver of a child living with Duchenne? Are you a teacher, TA, SENDCO or clinician working with someone living …
Take part in our Turning Point survey for a chance to win a £20 Amazon Voucher!Read More
Vamorolone NDA mid-cycle review meeting by FDA completed
Vamorolone NDA mid-cycle review meeting by FDA completed Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce the successful completion …
Vamorolone NDA mid-cycle review meeting by FDA completedRead More
RAF Falcons support Action Duchenne for their 2023 display season
Charity is very important to the RAF Falcons and every year they find time during their busy schedule to raise money for select charities nominated by …
RAF Falcons support Action Duchenne for their 2023 display seasonRead More
Yes I Can Residential Weekends 2023
Yes I Can is running 3 residential weekends as part of our transition to adulthood project. These are open to all 16-25 year olds living with Duchenne …
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy Dyne …
Happy Mother’s Day
Happy Mother's Day Today we celebrate all of the amazing Duchenne mummies in our community and want to let you know that we see the incredible job …
Moorside Primary school’s Holi celebrations raise money for Action Duchenne
Moorside Primary School in North Yorkshire had the amazing idea of combining their Holi celebrations with fundraising for Action Duchenne. Inspired by …
Moorside Primary school’s Holi celebrations raise money for Action DuchenneRead More
Santhera submits marketing authorisation application to the UK MHRA for Valmorolone in Duchenne Muscular Dystrophy.
Santhera submits marketing authorisation application to the UK MHRA for Valmorolone in Duchenne Muscular Dystrophy On March 2, 2023 – Santhera …
